SYF2 participates in the progress of diverse tumor entities, such as breast cancer (Shi et al., 2017), gastric cancer (GC) (Liu et al., 2019; Tao et al., 2020), human epithelial ovarian cancer (EOC) (Yan et al., 2015), hepatocellular carcinoma (Zhang et al., 2015), esophageal squamous cell carcinoma (ESCC) (Zhu et al., 2014), and glioma (Guo et al., 2014), in a cell cycle-dependent pathway. Here, SYF2 is linked to breast cancer.